Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects

Eye

Volumn 18, Issue 9, 2004, Pages 905-910

  Stewart, W C ^a,b   Day, D G ^c   Stewart, J A ^a   Holmes, K T ^a   Jenkins, J N ^a  

^a University of South Carolina   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Atlanta Research Company   (United States)

Author keywords

Brinzolamide; Dorzolamide; Ocular tolerability

Indexed keywords

BRINZOLAMIDE; DORZOLAMIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRY EYE; EYE BURNING; EYE IRRITATION; EYE PAIN; FATIGUE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MULTICENTER STUDY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PAIN ASSESSMENT; PHOTOSENSITIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TASTE DISORDER; UNPLEASANT SENSATION; VISUAL ACUITY; VISUAL ANALOG SCALE; VISUAL IMPAIRMENT;

EID: 4944230736     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6701353     Document Type: Article

References (22)

1. Lippa EA, Carlson LE, Ehinger B, Eriksson LO, Finnstrom K, Holmin C et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992; 110: 495.
2. Lippa EA, Schuman JS, Higginbotham EJ, Kass MA, Weinrib RN, Skuta GL et al. MK-507 versus sezolamide: a comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991; 98(3): 308.
3. Wilkerson M, Cyrlin M, Lippa EA, Esposito D, Deasy D, Panebianco D et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993; 111: 1343.
4. Kitazawa Y, Azuma I, Iwata K, Tsukahara S, Shioes Y, Araie M et al. Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose response study in patients with glaucoma or ocular hypertension. J Glaucoma 1994; 3: 275-279.
5. Strahlman E, Tipping R, Vogel R, the International Dorzolamide Study Group. A double masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995; 113: 1009-1016.
6. Laibovitz R, Strahlman ER, Barber BL, Strohmaier KM. Comparison of quality of life and patient preference of dorzolamide and pilocarpine as adjunctive therapy to timolol in the treatment of glaucoma. J Glaucoma 1995; 4: 306-313.
7. Shin DH, the Brinzolamide Adjunctive Therapy Study Group. A triple-masked, placebo-controlled, adjunctive therapy study of the efficacy and safety of TID-dosed brinzolamide 1.0% compared to TID-dosed placebo when used adjunctively to timolol 0.5%. Invest Ophthalmol Vis Sci (Suppl) 1997; 38: 2605.
8. Camras CB, the Brinzolamide Primary Therapy Study Group. A triple-masked, primary therapy study of the efficacy and safety of BID and TID-dosed brinzolamide 1% compared to TID-dosed dorzolamide 2% and BID-dosed timolol 0.5%. Invest Ophthalmol Vis Sci (Suppl) 1997; 38: 2605.
9. Stewart R, the Brinzolamide Comfort Study Group. The ocular comfort of the TID-dosed brinzolamide 1.0% compared to TID-dosed dorzolamide 2.0% in patients with primary open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci (Suppl) 1997; 38: 2603.
10. Scoville B, Krieglstein GK, Then E, Yokoyama S, Yokoyama T. Measuring drug-induced eye irritation: a simple new clinical assay. J Clin Pharmacol 1985; 25: 210-218.
11. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983; 17: 45-56.
12. Book SA. Essentials of Statistics. McGraw Hill Book Company: New York, 1978, pp 117-122, 205-215.
13. Rosner B. Fundamentals of Biostatistics. Duxbury Press: Boston, 1982, pp 336-341.
14. Siegel S. Nonparametric Statistics for the Behavioral Sciences. McGraw Hill Book Company: New York, 1956, pp 63-67.
15. Silver LH, the Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1988; 126: 400-408.
16. Michaud JE, Friren B, the International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 235-243.
17. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000; 22: 1204-1212.
18. Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, Mehta G. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 1983; 34(2): 234-239.
19. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimeters? Pain 1997; 72(1-2): 95-97.
20. Curtis P, Gartman LA, Green DB. Utilization of ketorolac tromethanine for control of severe odontogenic pain. J Endod 1994; 20(9): 457-459.
21. Seymour RA, Kelly PJ, Hawesford JE. The efficacy of ketoprofen and paracetamol (acetaminophen) in postoperative pain after third molar surgery. Br J Clin Pharmacol 1996; 41: 581-585.
22. Stubhaug A, Grimstad J, Breivik H. Lack of analgestic effect of 50 and 100 mg oral tramadol after orthopedic surgery: a randomized, double-blind, placebo and standard active drug comparison. Pain 1995; 62(1): 111-118.